公开(公告)号：US20230250105A1

公开(公告)日：2023-08-10

申请号：US18175030

申请日：2023-02-27

Applicant: UCB Biopharma SRL ,  SANOFI

Inventor： Daniel Christopher Brookings ,  Teresa De Haro Garcia ,  Yann Foricher ,  Helen Tracey Horsley ,  Martin Clive Hutchings ,  James Andrew Johnson ,  Malcolm Maccoss ,  Mengyang Xuan ,  Zhaoning Zhu

IPC: C07D487/18

CPC classification number: C07D487/18 ,  C07B2200/05

Abstract: A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20210252012A1

公开(公告)日：2021-08-19

申请号：US17176018

申请日：2021-02-15

Applicant: UCB Biopharma SRL ,  SANOFI

Inventor： Daniel Christopher Brookings ,  Teresa De Haro Garcia ,  Yann Foricher ,  Helen Tracey Horsley ,  Martin Clive Hutchings ,  James Andrew Johnson ,  Malcolm Maccoss ,  Mengyang Xuan ,  Zhaoning Zhu

IPC: A61K31/55 ,  C07D487/18

Abstract: A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US11912721B2

公开(公告)日：2024-02-27

申请号：US17102790

申请日：2020-11-24

Applicant: UCB Biopharma SRL ,  Sanofi

Inventor： Teresa De Haro Garcia ,  Michael Deligny ,  Jag Paul Heer ,  Joanna Rachel Quincey ,  Mengyang Xuan ,  Zhaoning Zhu ,  Daniel Christopher Brookings ,  Mark Daniel Calmiano ,  Yves Evrard ,  Martin Clive Hutchings ,  James Andrew Johnson ,  Sophie Jadot ,  Jean Keyaerts ,  Malcolm MacCoss ,  Matthew Duncan Selby ,  Michael Alan Shaw ,  Dominique Louis Leon Swinnen ,  Laurent Schio ,  Yann Foricher ,  Bruno Filoche-Romme

IPC: C07D519/00 ,  C07D491/08 ,  C07D487/08 ,  C07D491/18 ,  C07D495/08 ,  C07D471/18 ,  C07D487/18 ,  C07D493/18 ,  C07D495/18 ,  C07D513/18 ,  C07F7/18 ,  A61K31/4184 ,  A61K31/506 ,  A61K31/55

CPC classification number: C07D519/00 ,  A61K31/4184 ,  A61K31/506 ,  A61K31/55 ,  C07D471/18 ,  C07D487/08 ,  C07D487/18 ,  C07D491/08 ,  C07D491/18 ,  C07D493/18 ,  C07D495/08 ,  C07D495/18 ,  C07D513/18 ,  C07F7/1804

Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

公开(公告)号：US20210361668A1

公开(公告)日：2021-11-25

申请号：US17284950

申请日：2019-10-23

Applicant: UCB Biopharma SRL ,  SANOFI

Inventor： James Andrew Johnson ,  Ellen Olivia Gallimore ,  Mengyang Xuan

IPC: A61K31/55 ,  C07D471/18

Abstract: A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNF a activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20210155637A1

公开(公告)日：2021-05-27

申请号：US17102790

申请日：2020-11-24

Applicant: UCB Biopharma SRL ,  Sanofi

Inventor： Teresa De Haro Garcia ,  Michael Deligny ,  Jag Paul Heer ,  Joanna Rachel Quincey ,  Mengyang Xuan ,  Zhaoning Zhu ,  Daniel Christopher Brookings ,  Mark Daniel Calmiano ,  Yves Evrard ,  Martin Clive Hutchings ,  James Andrew Johnson ,  Sophie Jadot ,  Jean Keyaerts ,  Malcolm Mac Coss ,  Matthew Duncan Selby ,  Michael Alan Shaw ,  Dominique Louis Leon Swinnen ,  Laurent Schio ,  Yann Foricher ,  Bruno Filoche-Romme

IPC: C07D519/00 ,  C07F7/18 ,  C07D491/08 ,  A61K31/4184 ,  A61K31/506 ,  A61K31/55 ,  C07D487/08 ,  C07D491/18 ,  C07D495/08 ,  C07D471/18 ,  C07D487/18 ,  C07D493/18 ,  C07D495/18 ,  C07D513/18

Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

公开(公告)号：US10953019B2

公开(公告)日：2021-03-23

申请号：US16487988

申请日：2018-03-14

Applicant: UCB Biopharma SRL ,  Sanofi

Inventor： Julien Alistair Brown ,  Daniel Christopher Brookings ,  Jag Paul Heer ,  James Andrew Johnson ,  Zhaoning Zhu

IPC: A61K31/55 ,  C07D471/22

Abstract: A series of substituted fused pentacyclic imidazopyridine and imidazopyridazine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US11554122B2

公开(公告)日：2023-01-17

申请号：US17284950

申请日：2019-10-23

Applicant: UCB Biopharma SRL ,  SANOFI

Inventor： James Andrew Johnson ,  Ellen Olivia Gallimore ,  Mengyang Xuan

IPC: A61K31/55 ,  C07D471/18 ,  C07D487/18

Abstract: A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNF a activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US10906919B2

公开(公告)日：2021-02-02

申请号：US16220847

申请日：2018-12-14

Applicant: UCB Biopharma SRL ,  Sanofi

Inventor： Teresa De Haro Garcia ,  Michael Deligny ,  Jag Paul Heer ,  Joanna Rachel Quincey ,  Mengyang Xuan ,  Zhaoning Zhu ,  Daniel Christopher Brookings ,  Mark Daniel Calmiano ,  Yves Evrard ,  Martin Clive Hutchings ,  James Andrew Johnson ,  Sophie Jadot ,  Jean Keyaerts ,  Malcolm Mac Coss ,  Matthew Duncan Selby ,  Michael Alan Shaw ,  Dominique Louis Leon Swinnen ,  Laurent Schio ,  Yann Foricher ,  Bruno Filoche-Romme

IPC: C07D519/00 ,  C07F7/18 ,  C07D491/08 ,  A61K31/4184 ,  A61K31/506 ,  A61K31/55 ,  C07D487/08 ,  C07D491/18 ,  C07D495/08 ,  C07D471/18 ,  C07D487/18 ,  C07D493/18 ,  C07D495/18 ,  C07D513/18

Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

公开(公告)号：US10980814B2

公开(公告)日：2021-04-20

申请号：US16497217

申请日：2018-04-24

Applicant: UCB Biopharma SRL ,  SANOFI

Inventor： Daniel Christopher Brookings ,  Teresa De Haro Garcia ,  Yann Foricher ,  Helen Tracey Horsley ,  Martin Clive Hutchings ,  James Andrew Johnson ,  Malcolm Maccoss ,  Mengyang Xuan ,  Zhaoning Zhu

IPC: C07D487/18 ,  A61K31/55

Abstract: Disclosed herein are compounds of formula (I) and pharmaceutically acceptable salt thereof, wherein variables X, R1, R2, and R3 are defined herein. These compounds are potent modulators of human TNFα activity and, accordingly, of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20240140951A1

公开(公告)日：2024-05-02

申请号：US18267235

申请日：2021-12-06

Applicant: UCB Biopharma SRL

Inventor： Gareth Neil Brace ,  Shuyu Chu ,  Anne Marie Foley ,  James Andrew Johnson ,  Timothy John Norman ,  Joanna Rachel Quincey ,  James Thomas Reuberson ,  Robert Straker ,  Robert James Townsend

IPC: C07D487/04 ,  A61P29/00 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61P29/00 ,  C07D519/00

Abstract: A series of substituted imidazo[1,2-b]pyridazine derivatives as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.